22
Bob Roopra Director of Business Development Creavo Medical Technologies Ltd governmentevents.co.uk | 0330 0584 285 | [email protected]
Bob RoopraDirector of Business
Development Creavo Medical Technologies Ltd
governmentevents.co.uk | 0330 0584 285 | [email protected]
MCG at the point of careDate 6th December 2018
Who is Creavo
Who is Creavo
Creavo Medical Technologies 2018 - Confidential 4
• 2020 House Coventry
• A specialist magnetocardiography (MCG) company
• The first to deliver MCG at the point of care
• Performed the largest MCG study
• Launching commercial product in 2019
• Offices in Coventry and Leeds
Who are Creavo - achievements
2014
Apr 2014Company created as spin out from University of LeedsInitial £1.6m “seed funding”
2015 2016 2017
Feb 201560 60 clinical study completed at Leeds
Jul 2015“Series A” fundraise closes £4.6M investment
Aug 2016Company
rebrands as Creavo
Jan 2017Start of adoptive study
May 2017“Series B” fundraise closes £13.4M investment
Oct 2017Vitalscan receives FDA 510K Approval
Oct 2014Medical advisory board established
Apr 2015Business relocates to Warwick
Jul 201520 20 clinical study completed at Leeds
Feb 2016Company received ISO 13485
Nov 2016Vitalscan
receives CE Mark
May 2017US Creavo affiliate established
Aug 2017First ESC and EUSEM attendances
2016 Finalist
Awardswon
Start up award
2016 WinnerInnovation award
2016 Winner
2016 Winner
Healthcare Tech award
2017 Winner
Emerging Tech award
2017 Winner
Jan 20162020 House openedin Coventry
5Creavo Medical Technologies 2018 - Confidential
Who are Creavo – medical advisory board
Creavo Medical Technologies 2018 - Confidential6
Asc Prof Faizel OsmanConsultant Cardiologist / Electrophysiologist University Hospitals Coventry
Dr Richard CharlesEmeritus Consultant CardiologistLiverpool Heart and Chest HospitalChair of the MAB
Dr Rob HendersonConsultant Cardiologist Trent Cardiac Centre, Nottingham
Prof Rod StablesProfessor Interventional Cardiology, Liverpool Heart & Chest Hospital,
Dr Francis MorrisClinical Director Emergency Department, Sheffield
Prof John CammProfessor Clinical CardiologySt Georges Hospital, London
What is MCG
Quick non invasive technique
What is MCG - benefits
Creavo Medical Technologies 2018 - Confidential8
Not attenuated by body mass
Contains more data than a conventional ECG
3000 + citations of value in medicine
Measure of the magnetic field generated by
the hearts electrical activity
What is MCG - leveraging proven technology
Creavo Medical Technologies 2018 - Confidential 9
• Historic SQUID technology
• Very expensive to buy & run
• Use liquid cryogens
• Fixed asset can not be deployed
Found home in extensive research
• 3,684 Public domain references
• 190 Ischemic Heart Disease applicable to human with supporting data etc.
• Implications for clinical adoption
Clinical magnetometry developed in mid 70’s
What is MCG – visualising ischaemia a new wayA – Young healthy hearts
B – Older healthy hearts
C – Unstable Angina (UA)
D – NSTEMI
10Creavo Medical Technologies 2018 - Confidential
Lim, H. K., H. Kwon, N. Chung, Y.-G. Ko, J.-M. Kim, I.-S. Kim and Y.-K. Park (2009). "Usefulness of Magnetocardiogram to Detect Unstable Angina
Pectoris and Non-ST Elevation Myocardial Infarction." The American Journal of Cardiology 103(4): 448-454.
What is MCG – Creavo evolving the technology
Early Basic Research University of Leeds Creavo Medical Technologies
40 years of SQUID technology
development provides a
substantial body of clinical evidence
1970 +
Initial research
2010
Early patient ready device
2012
Launch* platform
2019
Clinical research device 2016
1st
Deployable MCG
Creavo Medical Technologies 2018 - Confidential 11
*Regulatory approval pending
What can Corsens do for healthcare
What can Corsens do for healthcare?
13
“The ability to quickly risk stratify and safely discharge ED patients presenting ….. chest pain of cardiac origin is critically important to the overall flow of patients through crowded Emergency Departments.”
Prof Greg J Ferman MD Professor Emergency Medicine University of Cincinnati
6%
60%
ED patients present with chest pain1
Of chest pain patients are admitted from ED to the
main hospital2
Chest pain triage costs global healthcare providers £9 billion3 per year
Creavo Medical Technologies 2018 - Confidential
Patient attends ED with chest pain
ECG
Clinical Assessment
What can Corsens do for healthcare – ED chest pain pathway
14
Clear Cardiac Problem on ECG (STEMI)
Emergency Department.
Cardiac Pathway
1st biomarker
2nd biomarker
Cardiac Revascularisation
Rapid Access Chest Pain Clinic
Main Hospital
Creavo Medical Technologies 2018 - Confidential
What can Corsens do for healthcare – an early “RULE-OUT” 3,4
15
Patient attends ED with chest pain
MCG
ECG
Clinical Assessment
Clear Cardiac Problem on ECG (STEMI)
Emergency Department.
RULE-OUT
Cardiac Pathway
1st biomarker
2nd biomarker
Cardiac Revascularisation
Rapid Access Chest Pain Clinic
Main Hospital
Creavo Medical Technologies 2018 - Confidential
What can Corsens do for healthcare
No Ischaemia or inactive SA
Active Stable Angina (SA)
Unstable Angina (UA)
NSTEMI STEMI
Assessment
12 Lead ECG ✓
Hs-cTn ✓ ✓
MCG RULE-OUT ✓ ✓ ✓ ✓
16
Non-ST Elevation MI (NSTEMI)
Unstable AnginaStable AnginaNon-ischaemia ST Elevation MI (STEMI)
Acute Coronary Syndromes
Emergency DepartmentRACPC / CardiologyLocation
Creavo Medical Technologies 2018 - Confidential
What can Corsens do for healthcare – savings for hospitals5
annual presentations to the Emergency
Department
128,000 7,680patients enter cardiac
triage
4,608
patients present with chest pain
patients RULED OUT early with MCG
circa1,000
“average UK hospital”* saving in excess of £500k per year
17
* Note: numbers include rounding, example selected is Doncaster And Bassetlaw Teaching Hospitals NHS Foundation Trust
Creavo Medical Technologies 2018 - Confidential
What’s next
What’s next – building on a large body of clinical evidence6
19
1970s 2010 2012
Sound body of research
2016 2019
Initial research DevelopmentSQUIDs
Technological Transformation
20212023
2025
Screening applications
Commercialisation
Targeted focus in Cardiology
Creavo Medical Technologies 2018 - Confidential
What’s next – a pipeline addressing many market opportunities
20
Electro-physiology
Screening
Ischaemia
Emergency Department
Cardiology Department
Rapid Access Chest Pain Clinic
Implantable Devices
Research Management
EP
Cardiotoxicity
Cardiac Health
Foetal Cardiac
Creavo Medical Technologies 2018 - Confidential
References1. Goodacre S, Cross E, Arnold J, Lewis C, Nicholl J , Capewell S, “Effectiveness and safety of chest pain assessment to
prevent emergency admissions: ESCAPE cluster randomised trial,” BMJ 2007;335:659 (2007)
2. Goodacre S, Cross E, Arnold J, et al. “The health care burden of acute chest pain,” Heart 2005;91:229-230 (2005)
3. Ghasemi-Roudsari S, Al-Shimary A, Varcoe B, Byrom R, Kearney L, Kearney M “A portable prototype magnetometer to differentiate ischemic and non-ischemic heart disease in patients with chest pain,” PLoS ONE 13(1): e0191241 (2018)
4. UK Adoptive Study estimate based on learning set data (on file), awaiting final validation data set result
5. Company estimates
6. Unpublished internal analysis. A. John Camm et al. “Magnetocardiography for Detection and Rule-Out of Acute Coronary Syndrome and Significant Coronary Artery Disease: Systematic Review and Meta-Analysis" (2017)
22
